Results 11 to 20 of about 14,967 (152)

Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal

Periodontology 2000, EarlyView., 2023
Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra, Hélène Rangé, Giuseppina Caligiuri, Philippe Bouchard   +3 more
wiley   +1 more source

Fluorescence quenching-based immunological probe for ticagrelor monitoring

Frontiers in Bioengineering and Biotechnology, 2023
Introduction: Ticagrelor is extensively utilized for the treatment of acute coronary syndromes (ACS), but its platelet aggregation inhibitory effects can potentially result in tissue bleeding, posing a serious risk to patients’ lives.Methods: In this ...
Shengshuo Zhang, Shengshuo Zhang, Yueqing Cheng, Yujie Gao, Yujie Zou, Weiling Xiao, Tianyi Li, Mei Li, Bowen Yu, Jinhua Dong, Jinhua Dong   +10 more
doaj   +1 more source

Effects of different doses of ticagrelor on platelet aggregation and endothelial function in diabetic patients with stable coronary artery disease

Platelets, 2019
We performed this study to observe the effects of different doses of ticagrelor and standard-dose clopidogrel on platelet reactivity and endothelial function in diabetic patients with stable coronary artery disease (CAD).
Meijiao He, Dan Li, Yingli Zhang, Danghui Sun, Guangzhong Liu, Yujiao Pan, Jing Shi, Yanyan Li, Shuangli Yin, Yue Li   +9 more
doaj   +1 more source

Clopidogrel versus ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry

Platelets, 2022
The benefits of potent antithrombotic therapy usually come at the expense of a higher risk of bleeding. The efficacy and safety of ticagrelor in elderly East Asian populations remains debated due to the concerns about the imbalance of ischemic and ...
Ziwei Xi, Zifeng Qiu, Jianan Li, Hong Qiu, Tingting Guo, Yong Wang, Jianfeng Zheng, Yanan Gao, Runlin Gao   +8 more
doaj   +1 more source

A Potential Mechanism of High-Dose Ticagrelor in Modulating Platelet Activity and Atherosclerosis Mediated by Thymic Stromal Lymphopoietin Receptor. [PDF]

PLoS ONE, 2015
Abnormal expression of thymic stromal lymphopoietin (TSLP) and its receptor (TSLPR) was found in patients with acute coronary syndrome. Ticagrelor, an oral platelet ADP P2Y12 receptor antagonist, is widely used in these patients.
Yi Mao, Yudong Peng, Qiutang Zeng, Longxian Cheng, Boyuan Wang, Xiaobo Mao, Kai Meng, Yuzhou Liu, Yitian Lian, Dazhu Li   +9 more
doaj   +1 more source

Successful Use of Recombinant Activated Factor VII to Reverse Ticagrelor-Induced Bleeding Risk: A Case Report

TH Open, 2018
Management of ticagrelor-associated bleeding is challenging, especially in neurosurgery. Platelet transfusion is inefficient and no antidote is currently available.
Anne Godier, Mélanie Dupont, Jean-Philippe Desilles, Caroline Le Guerinel, Guillaume Taylor, Mathilde Perrin, Anne-Céline Martin, Pascale Gaussem   +7 more
doaj   +1 more source

Ticagrelor reduces doxorubicin-induced pyroptosis of rat cardiomyocytes by targeting GSK-3β/caspase-1

Frontiers in Cardiovascular Medicine, 2023
Doxorubicin (Dox) is a widely used clinical drug whose cardiotoxicity cannot be ignored. Pyroptosis (inflammatory cell death) has gradually gained attention in the context of Dox-induced cardiotoxicity.
Shu-hui Wang, Meng-jin Sun, Si-yue Ding, Chun-li Liu, Jing-min Wang, Sheng-na Han, Xi Lin, Qian Li   +7 more
doaj   +1 more source

Efficacy and safety of standard and low dose ticagrelor versus clopidogrel in east AsianPatients with chronic total occlusion undergoing percutaneous coronary intervention: a single center retrospective study

BMC Cardiovascular Disorders, 2020
Background Patients with coronary chronic total occlusion (CTO) require effective antiplatelet therapy after percutaneous coronary intervention (PCI). Ticagrelor has more pronounced platelet inhibition than clopidogrel. However, the most appropriate dose
Yong Wang, Hong-wei Zhao, Cheng-fu Wang, Xiao-jiao Zhang, Jie Tao, Chun-sheng Cui, Qing-kun Meng, Yu Zhu, De-feng Luo, Ai-jie Hou, Bo Luan   +10 more
doaj   +1 more source

Ischemic and Bleeding Events of Ticagrelor Monotherapy in Korean Patients With and Without Diabetes Mellitus: Insights From the TICO Trial

Frontiers in Pharmacology, 2021
Background: Ticagrelor monotherapy after 3 months dual antiplatelet therapy (DAPT) with aspirin and ticagrelor can reduce bleeding without increasing ischemic events after percutaneous coronary intervention (PCI).
Kyeong Ho Yun, Jae Young Cho, Seung Yul Lee, Sang Jae Rhee, Byeong Keuk Kim, Myeong Ki Hong, Yangsoo Jang, Seok Kyu Oh, the TICO Investigators   +8 more
doaj   +1 more source

Validation of an HPLC–MS/MS Method for the Determination of Plasma Ticagrelor and Its Active Metabolite Useful for Research and Clinical Practice

Molecules, 2021
Ticagrelor is an antiplatelet agent which is extensively metabolized in an active metabolite: AR-C124910XX. Ticagrelor antagonizes P2Y12 receptors, but recently, this effect on the central nervous system has been linked to the development of dyspnea ...
Jennifer Lagoutte-Renosi, Bernard Royer, Vahideh Rabani, Siamak Davani   +3 more
doaj   +1 more source